Miguel Lpez-Botet

List of Publications by Year in Descending Order

150 papers	11,398 citations	53 h-index	104 g-index
160 ext. papers	12,835 ext. citations	6.8 avg, IF	5.59 L-index

#	Paper	IF	Citations
150	Reduced expansion of CD94/NKG2C NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions. *International Journal of Laboratory Hematology*, **2021**, 43, 1032-1040	2.5	2
149	Complete genomic characterization of a new KLRC2 allele, NKG2C*03. *Hla*, **2021**, 98, 259-261	1.9	1
148	NK cells eliminate Epstein-Barr virus bound to B cells through a specific antibody-mediated uptake. *PLoS Pathogens*, **2021**, 17, e1009868	7.6	3
147	Long-Term Evolution of the Adaptive NKG2C NK Cell Response to Cytomegalovirus Infection in Kidney Transplantation: An Insight on the Diversity of Host-Pathogen Interaction. *Journal of Immunology*, **2021**, 207, 1882-1890	5.3	0
146	CD137 Costimulation Counteracts TGF□Inhibition of NK-cell Antitumor Function. *Cancer Immunology Research*, **2021**, 9, 1476-1490	12.5	2
145	Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients. *Respiratory Research*, **2020**, 21, 63	7.3	2
144	Haplotype-Based Analysis of -Gene Profiles in a South European Population-Distribution of Standard and Variant Haplotypes, and Identification of Novel Recombinant Structures. *Frontiers in Immunology*, **2020**, 11, 440	8.4	10
143	Impact of cytomegalovirus infection on B cell differentiation and cytokine production in multiple sclerosis. *Journal of Neuroinflammation*, **2020**, 17, 161	10.1	9
142	Pretransplant adaptive NKG2C+ NK cells protect against cytomegalovirus infection in kidney transplant recipients. *American Journal of Transplantation*, **2020**, 20, 663-676	8.7	11
141	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). *European Journal of Immunology*, **2019**, 49, 1457-1973	6.1	485
140	High Numbers of Circulating CD57 NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2 Primary Breast Cancer. *Cancer Immunology Research*, **2019**, 7, 1280-1292	12.5	15
139	Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study. *Scientific Reports*, **2019**, 9, 7453	4.9	3
138	Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes. *Frontiers in Immunology*, **2019**, 10, 687	8.4	17
137	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. *OncoImmunology*, **2019**, 8, 1599636	7.2	15
136	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. *OncoImmunology*, **2019**, 8, e1593810	7.2	19
135	Adaptive Features of Natural Killer Cells in Multiple Sclerosis. *Frontiers in Immunology*, **2019**, 10, 2403	8.4	11
134	Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL). *Blood*, **2019**, 134, 5457-5457	2.2	0

133	NK Cell Infiltrates and HLA Class I Expression in Primary HER2 Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. *Clinical Cancer Research*, **2019**, 25, 1535-1545	12.9	49
132	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. *OncoImmunology*, **2018**, 7, e1395125	7.2	19
131	Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'. *European Journal of Neurology*, **2018**, 25, 925-933	6	11
130	Targeting NK-cell checkpoints for cancer immunotherapy. *Current Opinion in Immunology*, **2017**, 45, 73-81	7.8	118
129	Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles. *Journal of Immunology*, **2017**, 199, 656-665	5.3	17
128	Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. *Journal of Immunology*, **2017**, 198, 94-101	5.3	33
127	Impact of Zygosity on Bimodal Phenotype Distributions. *Biophysical Journal*, **2017**, 113, 148-156	2.9	
126	Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. *Frontiers in Immunology*, **2017**, 8, 166	8.4	31
125	Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System. *Frontiers in Immunology*, **2017**, 8, 1317	8.4	14
124	Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. *Frontiers in Immunology*, **2017**, 8, 1544	8.4	38
123	Development of the adaptive NK cell response to human cytomegalovirus in the context of aging. *Mechanisms of Ageing and Development*, **2016**, 158, 23-6	5.6	9
122	Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers. *European Journal of Immunology*, **2016**, 46, 1681-90	6.1	12
121	Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets. *Journal of Immunology*, **2016**, 196, 3818-27	5.3	52
120	Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future. *Clinical Cancer Research*, **2016**, 22, 1831-3	12.9	4
119	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 741-52	5	13
118	Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβT and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. *Haematologica*, **2016**, 101, 371-81	6.6	67
117	Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. *Journal of Immunology*, **2015**, 194, 2715-24	5.3	81
116	Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. *American Journal of Transplantation*, **2015**, 15, 806-14	8.7	36

115	NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation. *Journal of Immunology*, **2015**, 195, 1676-84	5.3	43
114	Dynamics of the NK-cell subset redistribution induced by cytomegalovirus infection in preterm infants. *Human Immunology*, **2015**, 76, 118-23	2.3	12
113	The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. *Seminars in Immunology*, **2014**, 26, 145-51	10.7	79
112	NK receptors: tools for a polyvalent cell family. *Frontiers in Immunology*, **2014**, 5, 617	8.4	5
111	NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. *European Journal of Immunology*, **2013**, 43, 3268-78	6.1	66
110	Functional impact of A91V mutation of the PRF1 perforin gene. *Human Immunology*, **2013**, 74, 14-7	2.3	12
109	Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction. *European Journal of Immunology*, **2013**, 43, 1133-41	6.1	102
108	Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2653-9	9.4	30
107	Priming of NK cell anti-viral effector mechanisms by direct recognition of human cytomegalovirus. *Frontiers in Immunology*, **2013**, 4, 40	8.4	18
106	Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction. *Tissue Antigens*, **2012**, 80, 184-7		30
105	Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children. *European Journal of Immunology*, **2012**, 42, 3256-66	6.1	64
104	CMV and Immunosenescence: from basics to clinics. *Immunity and Ageing*, **2012**, 9, 23	9.7	112
103	Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. *Journal of Immunology*, **2012**, 188, 4412-20	5.3	61
102	KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression. *Frontiers in Immunology*, **2012**, 3, 289	8.4	29
101	The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope. *Journal of Virology*, **2012**, 86, 4091-101	6.6	16
100	Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. *Journal of Leukocyte Biology*, **2011**, 90, 717-26	6.5	54
99	Natural killer cell receptor expression reflects the role of human cytomegalovirus in the pathogenesis of a subset of CD4+ T-cell large granular lymphocytosis. *Human Immunology*, **2011**, 72, 226-8	2.3	4
98	NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. *Blood*, **2011**, 117, 848-56	2.2	98

97	MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. *Allergy: European Journal of Allergy and Clinical Immunology*, **2011**, 66, 596-604	9.3	115
96	Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. *Clinical Immunology*, **2011**, 141, 348-56	9	43
95	Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 2314-21	9.4	27
94	Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. *Journal of Immunology*, **2010**, 185, 5392-404	5.3	23
93	Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. *Blood*, **2010**, 115, 5170-9	2.2	48
92	Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. *Clinical Immunology*, **2010**, 137, 41-50	9	22
91	Functional analysis of the CD300e receptor in human monocytes and myeloid dendritic cells. *European Journal of Immunology*, **2010**, 40, 722-32	6.1	22
90	Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. *European Journal of Immunology*, **2010**, 40, 1418-27	6.1	67
89	IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function. *Journal of Immunology*, **2009**, 182, 829-36	5.3	47
88	Multiple sclerosis associates with LILRA3 deletion in Spanish patients. *Genes and Immunity*, **2009**, 10, 579-85	4.4	37
87	Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. *Journal of Immunology*, **2007**, 178, 4402-10	5.3	45
86	The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. *Journal of Immunology*, **2007**, 178, 4473-81	5.3	105
85	The IREM-1 (CD300f) inhibitory receptor associates with the p85alpha subunit of phosphoinositide 3-kinase. *Journal of Immunology*, **2007**, 178, 808-16	5.3	44
84	Reply to Mela and Goodier. *Journal of Infectious Diseases*, **2007**, 195, 159-160	7	9
83	Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). *Journal of Autoimmunity*, **2007**, 29, 97-105	15.5	28
82	Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. *European Journal of Immunology*, **2006**, 36, 3198-206	6.1	83
81	Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. *Journal of Infectious Diseases*, **2006**, 194, 38-41	7	220
80	CEACAM1 in cervical cancer and precursor lesions: association with human papillomavirus infection. *Journal of Histochemistry and Cytochemistry*, **2006**, 54, 1393-9	3.4	11

79	Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. *Blood*, **2006**, 107, 3624-31	2.2	320
78	NK cell receptors involved in the response to human cytomegalovirus infection. *Current Topics in Microbiology and Immunology*, **2006**, 298, 207-23	3.3	52
77	Receptores específicos para moléculas HLA de clase I en la artritis reumatoide. *Seminarios De La Fundación Española De Reumatología*, **2005**, 6, 20-27		2
76	The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. *European Journal of Immunology*, **2005**, 35, 2071-80	6.1	54
75	Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1. *Journal of Leukocyte Biology*, **2005**, 77, 748-58	6.5	29
74	Signalling via CD70, a member of the TNF family, regulates T cell functions. *Journal of Leukocyte Biology*, **2004**, 76, 263-70	6.5	26
73	Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. *Tissue Antigens*, **2004**, 63, 195-203		85
72	IREM-1 is a novel inhibitory receptor expressed by myeloid cells. *European Journal of Immunology*, **2004**, 34, 3690-701	6.1	65
71	Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. *Biochemical and Biophysical Research Communications*, **2004**, 324, 640-7	3.4	33
70	Molecular characterization of a novel immune receptor restricted to the monocytic lineage. *Journal of Immunology*, **2004**, 173, 6703-11	5.3	46
69	Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. *Blood*, **2004**, 104, 3664-71	11.2	588
68	Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. *European Journal of Immunology*, **2003**, 33, 2744-54	6.1	57
67	Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. *Journal of Immunological Methods*, **2002**, 264, 109-19	2.5	32
66	Human T cell receptor-mediated recognition of HLA-E. *European Journal of Immunology*, **2002**, 32, 936-44	6.1	88
65	Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. *Journal of Immunology*, **2002**, 168, 3351-9	5.3	47
64	Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. *Biochemical and Biophysical Research Communications*, **2002**, 296, 355-62	3.4	32
63	TCR specificity dictates CD94/NKG2A expression by human CTL. *Immunity*, **2002**, 17, 487-99	32.3	99
62	Human T cell receptor-mediated recognition of HLA-E **2002**, 32, 936		3

61	Molecular studies and NK cell function of a new case of TAP2 homozygous human deficiency. *Clinical and Experimental Immunology*, **2001**, 125, 274-82	6.2	19
60	Human cytomegalovirus and natural killer-mediated surveillance of HLA class I expression: a paradigm of host-pathogen adaptation. *Immunological Reviews*, **2001**, 181, 193-202	11.3	43
59	New nomenclature for MHC receptors. *Nature Immunology*, **2001**, 2, 661	19.1	63
58	Mitogen-activated protein kinase activity is involved in effector functions triggered by the CD94/NKG2-C NK receptor specific for HLA-E. *European Journal of Immunology*, **2000**, 30, 2842-8	6.1	16
57	The tyrosine kinase PYK-2/RAFTK regulates natural killer (NK) cell cytotoxic response, and is translocated and activated upon specific target cell recognition and killing. *Journal of Cell Biology*, **2000**, 149, 1249-62	7.3	70
56	NK cell recognition of non-classical HLA class I molecules. *Seminars in Immunology*, **2000**, 12, 109-19	10.7	135
55	Paired inhibitory and triggering NK cell receptors for HLA class I molecules. *Human Immunology*, **2000**, 61, 7-17	2.3	85
54	Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. *Gastroenterology*, **2000**, 118, 867-79	13.3	195
53	Natural killer cell activation and inhibition by receptors for MHC class I. *Current Opinion in Immunology*, **1999**, 11, 301-7	7.8	135
52	How do NK cells sense the expression of HLA-G class Ib molecules?. *Seminars in Cancer Biology*, **1999**, 9, 19-26	12.7	38
51	Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. *EMBO Journal*, **1999**, 18, 4250-60	13	266
50	NK cell mediated recognition of HLA class Ib molecules: role of CD94/NKG2 receptors. *Journal of Reproductive Immunology*, **1999**, 43, 167-73	4.2	8
49	The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. *European Journal of Immunology*, **1999**, 29, 277-83	6.1	294
48	A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. *Journal of Leukocyte Biology*, **1999**, 66, 375-81	6.5	136
47	The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells **1999**, 29, 277		1
46	Intrahepatic enhanced expression of beta2-microglobulin conformational epitope in acute liver allograft rejection: evidence of modulation by glucocorticoids. *Digestive Diseases and Sciences*, **1998**, 43, 1755-62	4	4
45	Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. *European Journal of Immunology*, **1998**, 28, 599-609	6.1	86
44	Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. *European Journal of Immunology*, **1998**, 28, 1280-91	6.1	99

43	HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. *European Journal of Immunology*, **1998**, 28, 2854-63	6.1	307
42	Structure of the human CD94 C-type lectin gene. *Immunogenetics*, **1998**, 47, 305-9	3.2	34
41	HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 5199-204	11.5	764
40	Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants **1998**, 28, 1280		1
39	A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. *Journal of Experimental Medicine*, **1997**, 186, 1809-18	16.6	773
38	Gammadelta T cell activation or anergy during infections: the role of nonpeptidic TCR ligands and HLA class I molecules. *Journal of Leukocyte Biology*, **1997**, 62, 287-91	6.5	23
37	The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. *Research in Immunology*, **1997**, 148, 155-9		5
36	Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. *Immunological Reviews*, **1997**, 155, 165-74	11.3	121
35	The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. *Immunologic Research*, **1997**, 16, 175-85	4.3	12
34	The human natural killer gene complex is located on chromosome 12p12-p13. *Immunogenetics*, **1997**, 46, 307-11	3.2	65
33	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. *Trends in Immunology*, **1997**, 18, 89-95		638
32	The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. *European Journal of Immunology*, **1997**, 27, 563-7	6.1	228
31	Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors. *European Journal of Immunology*, **1997**, 27, 2812-21	6.1	135
30	Functional resemblance between the Ig-related NK cell receptors specific for HLA class I molecules and the CD94 C-type lectin. *Chemical Immunology and Allergy*, **1996**, 64, 116-34		3
29	Functional analysis of alpha 1 beta 1 integrin in human natural killer cells. *European Journal of Immunology*, **1996**, 26, 2023-9	6.1	19
28	Expression and function of alpha 4/beta 7 integrin on human natural killer cells. *Immunology*, **1996**, 89, 96-104	7.8	26
27	Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C. *Journal of Experimental Medicine*, **1996**, 184, 93-100	16.6	193
26	Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. *European Journal of Immunology*, **1995**, 25, 2433-7	6.1	192

25	Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. *Journal of Experimental Medicine*, **1994**, 180, 545-55	16.6	189
24	Variability in the expression of a β2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon. *Hepatology*, **1993**, 17, 372-382	11.2	19
23	Signaling through the LFA-1 leucocyte integrin actively regulates intercellular adhesion and tumor necrosis factor-alpha production in natural killer cells. *European Journal of Immunology*, **1993**, 23, 1859-65	6.1	40
22	Costimulation of cAMP and protein kinase C pathways inhibits the CD3-dependent T cell activation and leads to a persistent expression of the AP-1 transcription factor. *Cellular Immunology*, **1993**, 149, 343-56	4.4	7
21	Expression of lymphocyte activation surface antigens in bronchoalveolar lavage and peripheral blood cells from young healthy subjects. *Chest*, **1993**, 104, 32-7	5.3	29
20	Phospholipase D activation in human natural killer cells through the Kp43 and CD16 surface antigens takes place by different mechanisms. Involvement of the phospholipase D pathway in tumor necrosis factor alpha synthesis. *Journal of Experimental Medicine*, **1992**, 176, 9-17	16.6	33
19	Functional analysis of peripheral blood lymphocytes isolated from patients with chronic hepatitis type B. *Digestive Diseases and Sciences*, **1992**, 37, 73-8	4	4
18	Identification of natural killer (NK) cells in lesions of human cutaneous graft-versus-host disease: expression of a novel NK-associated surface antigen (Kp43) in mononuclear infiltrates. *Journal of Investigative Dermatology*, **1991**, 97, 659-66	4.3	28
17	Expression of a novel activation antigen on intrahepatic CD8+ T lymphocytes in viral chronic active hepatitis. *Gastroenterology*, **1990**, 98, 1029-35	13.3	84
16	Induction of T cell function via the gp33/27 activation inducer molecule (AIM) requires co-expression of the CD3/TcR complex. *European Journal of Immunology*, **1989**, 19, 959-62	6.1	13
15	High toxic efficiency of ricin immunotoxins specific for the T-cell antigen receptor of a human leukemia T-cell line. *International Journal of Cancer*, **1989**, 43, 697-702	7.5	1
14	CD2 is involved in regulating cyclic AMP levels in T cells. *European Journal of Immunology*, **1988**, 18, 961-4	6.1	23
13	Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. *European Journal of Immunology*, **1988**, 18, 1791-6	6.1	127
12	Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. *Journal of Experimental Medicine*, **1988**, 168, 1621-37	16.6	244
11	Involvement of the CD4 molecule in a post-activation event on T cell proliferation. *European Journal of Immunology*, **1987**, 17, 179-86	6.1	98
10	Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation. *European Journal of Immunology*, **1987**, 17, 1167-74	6.1	13
9	An in vivo functional immune system lacking polyclonal T-cell surface expression of the CD3/Ti(WT31) complex. *Scandinavian Journal of Immunology*, **1987**, 26, 699-708	3.4	19
8	Involvement of T11 molecules in antigen receptor-mediated T lymphocyte functions: effect of anti-T11 monoclonal antibody on functional capabilities of alloreactive T cell clones. *European Journal of Immunology*, **1985**, 15, 841-4	6.1	20

7	Selection and characterization of monoclonal antibodies to the idiotype-like structure of an interleukin-2-producing human leukemia T-cell line. *International Journal of Cancer*, **1985**, 36, 253-9	7.5	26
6	Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen-receptor complex. *Journal of Experimental Medicine*, **1985**, 162, 823-38	16.6	140
5	Anticlonotypic monoclonal antibodies induce proliferation of clonotype-positive T cells in peripheral blood human T lymphocytes. Evidence for a phenotypic (T4/T8) heterogeneity of the clonotype-positive proliferating cells. *Journal of Experimental Medicine*, **1985**, 162, 1393-8	16.6	21
4	Interleukin 2 and interferon-gamma are not sufficient to induce natural killer-like activity in human T cell clones. *European Journal of Immunology*, **1984**, 14, 1137-41	6.1	5
3	Induction of natural killer-like cytotoxicity in cultured human thymocytes. *European Journal of Immunology*, **1983**, 13, 964-9	6.1	39
2	Natural killer-like cytotoxicity of human T-cell clones against various target cells. *Scandinavian Journal of Immunology*, **1983**, 17, 95-8	3.4	12
1	Removal of PHA from supernatants containing T-cell growth factor. *Journal of Immunological Methods*, **1981**, 40, 289-96	2.5	37